• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boehringer Ingelheim touts Stiolto Respimat data

September 6, 2016 By Sarah Faulkner

Boehringer Ingelheim RespimatBoehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath.

When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along with exercise, their exercise capacity increased by 45.8% compared to those receiving a placebo. The Physacto trial is a part of the Tovito Phase III clinical trial, investigating the efficacy of Respimat as a maintenance therapy for COPD.

“It is vital for people with COPD to stay active as this may help slow the progression of disease burden and reduce its impact on health,” trial investigator Dr. Thierry Troosters, of Belgium’s University of Leuven, said in prepared remarks. “This new study is the first to demonstrate that a holistic approach to COPD management, which includes behavior modification enriched with exercise training and effective long-action bronchodilator therapy, can improve exercise capacity, reduce shortness of breath and difficulty associated with daily activities.”

The participants were randomly placed into 4 groups: Respimat with or without exercise, Respimat alone, or placebo. Investigators measured exercise capacity using a walking test, in which participants walked at a standard speed for as long as they could. Exercise capacity improved 29% when people took Respimat without exercising, compared to the placebo arm. All 4 groups underwent a 12-week program that provided them with exercise strategies, such as using a pedometer.

The data were presented yesterday at the annual meeting of the European Respiratory Society in London. The results build on earlier studies done that show an improvement in exercise capacity associated with Respimat use.

Last week, Boehringer-Ingelheim announced a partnership with Qualcomm (NSDQ:QCOM) subsidiary Qualcomm Life to create an inhaler that can track user information, in an effort to help people with COPD adhere to their treatment regimen.

Filed Under: Clinical Trials, Drug-Device Combinations, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS